Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
…, F Sanchez-Toril, A McIvor, P Teichmann… - American journal of …, 2007 - atsjournals.org
… Post-bronchodilator FEV 1 increased by 39 ml with roflumilast compared with placebo by
52 weeks (p = 0.001). The mean exacerbation rate was low and comparable in both treatment …
52 weeks (p = 0.001). The mean exacerbation rate was low and comparable in both treatment …
[BOOK][B] Adiabatic logic: future trend and system level perspective
P Teichmann - 2011 - books.google.com
… As soon as the power-clock φ ramped from 0 to VDD reaches the threshold voltage Vth,p of
… Vth,p charge from the output out is restored to φ. A certain fraction of energy 12CoutV2th,p …
… Vth,p charge from the output out is restored to φ. A certain fraction of energy 12CoutV2th,p …
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus
…, D Bredenbröker, P Teichmann… - The Journal of …, 2012 - academic.oup.com
Context: The phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory
treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic …
treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic …
[HTML][HTML] TRAIL induces nuclear translocation and chromatin localization of TRAIL death receptors
U Mert, A Adawy, E Scharff, P Teichmann, A Willms… - Cancers, 2019 - mdpi.com
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma
membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-…
membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-…
[HTML][HTML] The Staphylococcus epidermidis transcriptional profile during carriage
P Teichmann, A Both, C Wolz, MW Hornef… - Frontiers in …, 2022 - frontiersin.org
The virulence factors of the opportunistic human pathogen Staphylococcus epidermidis
have been a main subject of research. In contrast, limited information is available on the …
have been a main subject of research. In contrast, limited information is available on the …
Fundamentals of adiabatic logic
P Teichmann, P Teichmann - Adiabatic Logic: Future Trend and System …, 2012 - Springer
… As soon as the power-clock ϕ ramped from 0 to V DD reaches the threshold voltage V th,p of
the … While ϕ is above V th,p charge from the output out is restored to ϕ. A certain fraction of …
the … While ϕ is above V th,p charge from the output out is restored to ϕ. A certain fraction of …
[HTML][HTML] Risk factors for neonatal Mortality in preterm newborns in the extreme South of Brazil
MR Tietzmann, PV Teichmann, CS Vilanova… - Scientific Reports, 2020 - nature.com
… The proportion of these early newborns remained stable among all births, while the
neonatal mortality rate for this group tended to decrease (p < 0.001). The adjusted risk was …
neonatal mortality rate for this group tended to decrease (p < 0.001). The adjusted risk was …
Sleep transistor circuits for fine-grained power switch-off with short power-down times
…, J Berthold, J Fischer, P Teichmann… - ISSCC. 2005 IEEE …, 2005 - ieeexplore.ieee.org
Fine-grained sleep transistor circuits are demonstrated with 0.12μm 16 b MAC (multiply-accumulate
unit). Standby power is reduced by a factor of 5500 at 85C with speed reduction of 5…
unit). Standby power is reduced by a factor of 5500 at 85C with speed reduction of 5…
Power-clock gating in adiabatic logic circuits
P Teichmann, J Fischer, S Henzler, E Amirante… - Integrated Circuit and …, 2005 - Springer
… of the p-channel Wp is twice Wn The p-channel width Wp of the transmission gate is twice
the width Wn of the n-channel to compensate for the differing mobilities of n-channel and p-…
the width Wn of the n-channel to compensate for the differing mobilities of n-channel and p-…
Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease
EFM Wouters, P Teichmann, M Brose… - C42. CHRONIC …, 2010 - atsjournals.org
RATIONALE: with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Roflumilast treatment is also associated with weight decrease that is not progressive and is …
Roflumilast treatment is also associated with weight decrease that is not progressive and is …